(S)-3-amino-4-oxo-4-(phenylamino)butanoic acid | 58889-24-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-amino-4-oxo-4-(phenylamino)butanoic acid
• 英文别名: L-Asparaginsaeure-α-anilid；N¹-phenyl-L-isoasparagine；L-Asparaginsaeure-1-anilid；N¹-Phenyl-L-isoasparagin；L-aspartyl-L-phenylamine；(3S)-4-anilino-3-azaniumyl-4-oxobutanoate
• CAS: 58889-24-0
• 化学式: C₁₀H₁₂N₂O₃
• 分子量: 208.217
• InChiKey: ZHMXJJSFAWDVAO-QMMMGPOBSA-N

物化性质

• 沸点：
  480.4±40.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (3S)-4-苯胺基-4-氧代-3-[(2,2,2-三氟乙酰基)氨基]丁酸 在 氨 、 水 作用下， 生成 (S)-3-amino-4-oxo-4-(phenylamino)butanoic acid
  参考文献：
  名称：

  Weygand et al., Chemische Berichte, 1957, vol. 90, p. 1879,1890

  摘要：

  DOI：

文献信息

• [EN] MODULATED RELEASE THERAPEUTIC AEROSOLS<br/>[FR] AEROSOLS THERAPEUTIQUES A LIBERATION MODULEE
  申请人：AEROPHARM TECHNOLOGY INC

  公开号：WO2002005785A1

  公开（公告）日：2002-01-24

  A modulated release aerosal formulation is disclosed. The formulation comprises a biodegradable ABA block copolymer having a selected medicament assocaited therewith, and a fluid carrier for carrying and delivering the construct.

  公开了一种调制释放气雾剂配方。该配方包括一种可生物降解的ABA嵌段共聚物，其中与所选药物相关联，并且还包括一种流体载体，用于携带和释放该构造。
• Both Amide-Bearing α- and β-Amino Acids from Natural Aspartic Acid Are Efficient Organocatalysts for Enantioselective Aldol Reactions
  作者：Gen-Fa Wen、Rui Zhang、Chao-Shan Da、Chu-Yu Zhang

  DOI：10.1055/a-1953-1656

  日期：2023.2

  of structurally similar α- and β-amino acids in an asymmetric aldol transformation. Interestingly, aspartic acid is not only an α-amino acid, but also a β-amino acid. Thus, by modifying one of the two acidic groups of aspartic acid, two sets of α- and β-amino acids, 14 amino acids in total, were prepared and used as organocatalysts. The two types of amino acid, interestingly, achieved similar high catalytic

  这项工作旨在比较和探索结构相似的α-和β-氨基酸在不对称醛醇转化中的不同催化效率。有趣的是，天冬氨酸不仅是一种α-氨基酸，也是一种β-氨基酸。因此，通过修饰天冬氨酸的两个酸性基团之一，制备了两组α-和β-氨基酸，总共14个氨基酸，并用作有机催化剂。有趣的是，这两种氨基酸在不同的最佳条件下在不对称醛醇转化中实现了相似的高催化效率。在某些情况下，理想的 β-氨基酸甚至比理想的 α-氨基酸实现了显着更高的对映选择性，尽管 α-氨基酸在这种不对称转化中被广泛证明是高效的有机催化剂。
• Calcium-supplemented beverages and beverage concentrates contaning low levels of sulfate
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0301653A1

  公开（公告）日：1989-02-01

  Beverages and beverage concentrates nutritionally supple­mented with significant levels of solubilized calcium and containing low levels of sulfate, preferably in combination with low levels of chloride, are disclosed. These beverages and concentrates also contain specified levels of edible acids selected from phosphoric acid, citric acid, malic acid, fumaric acid, adipic acid, gluconic acid, and lactic acid, as well as mixtures of these acids. The particular acid systems are selected to provide the desired flavor and sourness character for the beverages and concentrates. Inclusion of low levels of sulfate/chloride in these beverages and concentrates provides a quicker onset of sourness, prevents or reduces aftertaste effects and improves the solubility of the calcium, particularly when high levels of phosphoric acid or citric acid are used. Inclusion of sulfate/chloride also prevents or reduces the precipitation and deposition of calcium salts on equipment surfaces during the pasteurization or sterilization of calcium-containing fruit juice beverages.

  本发明公开了以大量溶解钙和低含量硫酸盐（最好与低含量氯化物结合使用）作为营养补充的饮料和浓缩饮料。这些饮料和浓缩物还含有特定含量的食用酸，这些酸选自磷酸、柠檬酸、苹果酸、富马酸、己二酸、葡萄糖酸和乳酸，以及这些酸的混合物。选择特定的酸体系是为了给饮料和浓缩物提供所需的风味和酸味特征。在这些饮料和浓缩物中加入低浓度的硫酸盐/盐酸盐，可以更快地产生酸味，防止或减少余味，并提高钙的溶解度，特别是在使用高浓度磷酸或柠檬酸时。在含钙果汁饮料的巴氏杀菌或灭菌过程中，加入硫酸盐/盐酸盐还能防止或减少钙盐在设备表面的沉淀和沉积。
• Thiazole derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0928790A1

  公开（公告）日：1999-07-14

  Compounds of formula I as well as pharmaceutically usable salts and esters thereof, wherein R1, R2 and R3 have the significance given in claim 1, inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. They can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumour metastasing, tumour growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure as well as infection caused by viruses, bacteria or fungi.

  式 I 的化合物及其药用盐和酯 及其药用盐和酯，其中 R1、R2 和 R3 具有权利要求 1 所述的意义，可抑制粘附蛋白与不同类型细胞表面的结合，并相应地影响细胞-细胞和细胞-基质之间的相互作用。它们可以药物制剂的形式用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、Paget 病、糖尿病视网膜病变、黄斑变性、血管介入后的再狭窄、牛皮癣、关节炎、纤维化、肾衰竭以及由病毒、细菌或真菌引起的感染。
• Modulated release particles for lung delivery
  申请人：——

  公开号：US20020110525A1

  公开（公告）日：2002-08-15

  A modulated release aerosol formulation is disclosed. The formulation comprises a polysaccharide polymer having a selected medicament associated therewith, a fluid carrier for carrying and delivering the construct and a stabilizer.

  本发明公开了一种调节释放气雾剂配方。该制剂包括一种多糖聚合物（其中含有一种选定的药物）、一种用于承载和输送构筑物的流体载体以及一种稳定剂。